TrialScientific reports2025

Palovarotene for patients with multiple hereditary exostosis: results of MO-Ped, a terminated, randomized, placebo-controlled, double-blind phase 2 trial.

Luca Sangiorgi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.